Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Gastrointestinal Neuroendocrine Tumor G1

Review the gastrointestinal neuroendocrine tumor g1 treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-5 of 5

Comparing Retreatment of 177Lu-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Status: Active
Location: 23 locations
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Status: Active
Location: 25 locations
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Status: Active
Location: 3 locations
177Lu-DOTATATE and Fulvestrant for the Treatment of Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee